NewAmsterdam Pharma CEO buys 10,000 shares

NewAmsterdam Pharma’s CEO added 10,000 NAMS shares in a reported open-market purchase and now holds both direct and trust-based positions.

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. (NAMS) reports that Chief Executive Officer and director Michael H. Davidson purchased 10,000 Ordinary Shares on September 14, 2026 at $22.65 per share in an open-market or private transaction. After this trade he directly holds 792,923 Ordinary Shares, including 163,352 subject to unvested restricted stock unit awards, and is also reported as indirectly holding 285,715 Ordinary Shares through the Michael H. Davidson 2026 Grantor Retained Annuity Trust.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 2 txns

Insider Davidson Michael H.

Role Chief Executive Officer

Bought 10,000 shs ($227K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares F1, F2	10,000	$22.65	$227K
holding	Ordinary Shares F3	--	--	--

Holdings After Transaction: Ordinary Shares — 792,923 shares (Direct); Ordinary Shares — 285,715 shares (Indirect, See footnote)

Footnotes (3)

1. F1. Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
2. F2. Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person.
3. F3. These Ordinary Shares are held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT"). The Reporting Person is the sole annuitant and trustee of the GRAT.

Key Figures

Shares purchased: 10,000 Ordinary Shares Purchase price per share: $22.65 per share Direct holdings after transaction: 792,923 Ordinary Shares +3 more

6 metrics

Shares purchased 10,000 Ordinary Shares Purchase by CEO Michael H. Davidson on September 14, 2026

Purchase price per share $22.65 per share Ordinary Shares bought on September 14, 2026

Direct holdings after transaction 792,923 Ordinary Shares Directly held by Michael H. Davidson following the September 14, 2026 purchase

Unvested RSU shares included in direct holdings 163,352 Ordinary Shares Subject to restricted stock unit awards that remain subject to vesting

Indirect holdings via 2026 GRAT 285,715 Ordinary Shares Held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust

Previously transferred from indirect to direct holdings 608,779 Ordinary Shares Transfer from Stichting Administratiekantoor EPNAP previously reported as indirectly beneficially owned

Key Terms

restricted stock unit awards, Grantor Retained Annuity Trust, beneficially owned

3 terms

restricted stock unit awards financial

"Includes 163,352 ordinary shares subject to restricted stock unit awards that remain"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

Grantor Retained Annuity Trust financial

"These Ordinary Shares are held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

beneficially owned financial

"ordinary shares previously reported as indirectly beneficially owned by the Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NewAmsterdam Pharma (NAMS) report for Michael H. Davidson?

The company reported that Michael H. Davidson, its Chief Executive Officer and a director, purchased 10,000 Ordinary Shares of NAMS on September 14, 2026 in an open-market or private transaction at $22.65 per share.

How many NewAmsterdam Pharma (NAMS) shares does the CEO hold directly after this Form 4?

After the reported transaction, Michael H. Davidson directly holds 792,923 Ordinary Shares of NewAmsterdam Pharma, which includes 163,352 Ordinary Shares subject to restricted stock unit awards that remain subject to vesting.

Does the NewAmsterdam Pharma (NAMS) CEO have indirect holdings reported on this Form 4?

Yes. The filing reports an indirect holding of 285,715 Ordinary Shares held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust, for which Michael H. Davidson is the sole annuitant and trustee.

Were the NAMS share purchases by the CEO made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not checked, and there is no footnote indicating a trading plan, so the filing does not report that the September 14, 2026 purchase was made under a Rule 10b5-1 plan.

What do the Form 4 footnotes say about the CEO’s previously reported indirect NAMS holdings?

One footnote states that the direct holding figure reflects a prior transfer of 608,779 Ordinary Shares that were previously reported as indirectly beneficially owned and held of record by Stichting Administratiekantoor EPNAP for the benefit of Michael H. Davidson.

How many NAMS shares in the CEO’s direct holdings are from unvested equity awards?

Within the CEO’s reported direct holding of 792,923 Ordinary Shares, 163,352 Ordinary Shares are subject to restricted stock unit awards that remain subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:30 PM Accepted by SEC EDGAR 09/15/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davidson Michael H.

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN 1411 DC

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/14/2026		P		10,000	A	$22.65	792,923(1)(2)	D
Ordinary Shares								285,715	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

2. Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person.

3. These Ordinary Shares are held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT"). The Reporting Person is the sole annuitant and trustee of the GRAT.

	/s/ Michael Marino as Attorney-in-Fact for Michael H. Davidson	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)